Immuneering unveils Deep Cyclic Inhibitor atebimetinib for first line pancreatic cancer at AACR meeting

Traders Union
All News
Companies
Immuneering targets pancreatic cancer

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Companies

Regulators News

Central Banks News

24.04.2026

Immuneering unveils Deep Cyclic Inhibitor atebimetinib for first line pancreatic cancer at AACR meeting — Immuneering targets pancreatic cancer

Immuneering has presented a poster at the AACR 2026 Annual Meeting that introduces its Deep Cyclic Inhibitor compound, atebimetinib, as a prospective advance for first line pancreatic cancer therapy.

The company suggests that this compound could enhance treatment durability, potentially reshaping patient outcomes in pancreatic cancer. This presentation underscores continued research activity in the field, with details available through the company's official communication channels.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Immuneering previously introduced its Deep Cyclic Inhibitor approach, targeting reduced toxicity in cancer therapy to help maintain patient quality of life, according to a company announcement. The company's CEO, Ben Zeskind, recently discussed early-stage research and innovative therapies for pancreatic cancer on a BrewMarkets podcast episode. These efforts highlight Immuneering's ongoing focus on advancing cancer treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Toncoin becomes Gram: Why Durov restored token's original name

By Anastasiia Chabaniuk
2 hours ago

Toncoin becomes Gram: Why Durov restored token's original name

Editors' Picks

Why Tether flipping Ethereum is a pivotal moment for crypto

By Kyle Torpey
23 hours ago

Why Tether flipping Ethereum is a pivotal moment for crypto

Editors' Picks

MiCA deadline: Why crypto companies are leaving Europe

By Eugene Komchuk
Yesterday

MiCA deadline: Why crypto companies are leaving Europe

Editors' Picks

All Editors' Top Picks

Latest Immuneering News

Andrew Gengos joins Immuneering as new chief financial officer

By Andrey Mastykin
15 hours ago

Andrew Gengos joins Immuneering as new chief financial officer

Companies

Immuneering draws attention as Mizuho analyst spotlights IMRX pancreatic cancer data at ASCO26

By Anastasiia Chabaniuk
29.05.2026

Immuneering draws attention as Mizuho analyst spotlights IMRX pancreatic cancer data at ASCO26

Companies

Immuneering achieves over twofold improvement in first-line pancreatic cancer survival in Phase 2a topline data

By Yulia Slavina
22.05.2026

Immuneering achieves over twofold improvement in first-line pancreatic cancer survival in Phase 2a topline data

Companies

All Immuneering News

Anastasiia Chabaniuk
2 hours ago

Toncoin becomes Gram: Why Durov restored token's original name

Kyle Torpey
23 hours ago

Why Tether flipping Ethereum is a pivotal moment for crypto

Eugene Komchuk
Yesterday

MiCA deadline: Why crypto companies are leaving Europe

Mikhail Vnuchkov
13.06.2026

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Eugene Komchuk
12.06.2026

The world's first trillionaire: How Musk built his fortune on electric cars, space and AI

Andreas Kristo
31 min ago

U.S. stocks hold steady on BoJ rate hike and China retail sales decline, Gary Black notes

Olga Shendetskaya
1 hour ago

SPCX offers tactical moves from IPO to Day 3, Scott Redler notes

Hanna Syniavska
1 hour ago

Industry changes delayed by crypto exchange scams, Gabor Gurbacs argues

Jose Antonio Gastelum
1 hour ago

BTC event features side events and parties, Francis Pouliot notes

Andreas Kristo
1 hour ago

Javier Blas: Murban crude from UAE shifts to contango as time spreads collapse

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
1 hour ago

U.S. judge dismisses Musk xAI suit against OpenAI

U.S. judge dismisses Musk xAI suit against OpenAI

Ivan Andriyenko
2 hours ago

U.S. futures steady as markets weigh Iran deal

U.S. futures steady as markets weigh Iran deal

Andrey Mastykin
3 hours ago

Oil slips as U.S.-Iran deal raises hopes for Hormuz reopening

Oil slips as U.S.-Iran deal raises hopes for Hormuz reopening

Eugene Komchuk
4 hours ago

Bitcoin rises to $66,000 after Bank of Japan rate hike

Bitcoin rises to $66,000 after Bank of Japan rate hike

Olga Shendetskaya
19 hours ago

Nvidia returns to bond market as AI borrowing wave grows

Nvidia returns to bond market as AI borrowing wave grows

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Euro remains under pressure ahead of Fed rate decision

Mykhailo Ihnatenko
Now

Quantum ambitions push Rolls-Royce toward record highs

Mykhailo Ihnatenko
Now

BT Group stands out as broadband rivals struggle

Mykhailo Ihnatenko
Now

Solana rebounds as markets await Fed decision

Anton Kharitonov
Now

Google gains as easing Middle East tensions support market sentiment

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.